All In Biotech

Drug Trial Radar · NCT01374581

Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria

A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains

Last checked: Nov 19, 2026Latest source record: Oct 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,117

Actual

Start

May 2012

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Lead sponsor
Universiteit AntwerpenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP); Fund for Scientific Research, Flanders, Belgium; Institute of Tropical Medicine, Belgium; University of Kinshasa; Centre Muraz; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Makerere University
First posted
Jun 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 months, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for example Arthemeter-Lumefantrine (AL) in Uganda (Ug) and artesunate-amodiaquine (ASAQ) in RDCongo, on malaria incidence and its potential selection of resistant strains. Patients will be followed-up for efficacy and safety during 42 days after treatment with the first line therapy recommended by the national authorities(arthemeter-lumefantrine in Uganda and artesunate-amodiaquine in RDCongo) and retreated the patients either with the same ACT or an other ACT or oral Quinine + clyndamicin. The investigators hypothesize that (re)treatment with the first line ACT treatment beyond 14 days is as efficacious as any other rescue treatment, without the risk of selecting drug resistant strains.

Conditions

  • Malaria

Interventions

  • Artemether/LumefantrineDrug

    Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk). Weight in kg Number of tablet per dose Age 5 to \< 15 kg 1 tablet per dose 15 to \< 25 kg 2 tablets per dose 25 to \< 35 kg 3 tablets per dose

  • Artesunate/AmodiaquineDrug

    Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to \< 9kg):1 tablet (25 mg/675mg) for 3 days 1 to 5 years (= 9 kg to \< 18 kg)1 tablet(25mg/67,5mg)for 3 days

  • Quinine + ClindamycinDrug

    this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow; Quinine: 9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose Clindamycin syrup: 10 mg/kg twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Late Parasitological FailureTime frame: Day4-Day28

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre de Santé Lisungi

    Kinshasa, Mont-Ngafula, Republic of the Congo

  • Kazo Health centre IV

    Kiruhura, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.